305 related articles for article (PubMed ID: 36232833)
1. The Potential Roles of Extracellular Vesicles as Biomarkers for Parkinson's Disease: A Systematic Review.
Valencia J; Ferreira M; Merino-Torres JF; Marcilla A; Soriano JM
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232833
[TBL] [Abstract][Full Text] [Related]
2. Potential of extracellular vesicles in the Parkinson's disease - Pathological mediators and biomarkers.
Zhao Y; Yang G
Neurochem Int; 2021 Mar; 144():104974. PubMed ID: 33485881
[TBL] [Abstract][Full Text] [Related]
3. α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson's disease.
Cao Z; Wu Y; Liu G; Jiang Y; Wang X; Wang Z; Feng T
Neurosci Lett; 2019 Mar; 696():114-120. PubMed ID: 30579996
[TBL] [Abstract][Full Text] [Related]
4. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
Sharma N; Rao SP; Kalivendi SV
Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial Dysfunction, Protein Misfolding and Neuroinflammation in Parkinson's Disease: Roads to Biomarker Discovery.
Picca A; Guerra F; Calvani R; Romano R; Coelho-Júnior HJ; Bucci C; Marzetti E
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680141
[TBL] [Abstract][Full Text] [Related]
6. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
7. microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.
Leggio L; Vivarelli S; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Marchetti B; Iraci N
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29236052
[TBL] [Abstract][Full Text] [Related]
8. Protein-protein interactions regulating α-synuclein pathology.
Wang J; Dai L; Chen S; Zhang Z; Fang X; Zhang Z
Trends Neurosci; 2024 Mar; 47(3):209-226. PubMed ID: 38355325
[TBL] [Abstract][Full Text] [Related]
9. Glycoconjugate journal special issue on: the glycobiology of Parkinson's disease.
Brockhausen I; Schutzbach J; Wang J; Fishwick B; Brockhausen J
Glycoconj J; 2022 Feb; 39(1):55-74. PubMed ID: 34757539
[TBL] [Abstract][Full Text] [Related]
10. Differential expression and significance of miRNAs in plasma extracellular vesicles of patients with Parkinson's disease.
Xie S; Niu W; Xu F; Wang Y; Hu S; Niu C
Int J Neurosci; 2022 Jul; 132(7):673-688. PubMed ID: 33045885
[TBL] [Abstract][Full Text] [Related]
11. Molecular chaperones and Parkinson's disease.
Hu S; Tan J; Qin L; Lv L; Yan W; Zhang H; Tang B; Wang C
Neurobiol Dis; 2021 Dec; 160():105527. PubMed ID: 34626793
[TBL] [Abstract][Full Text] [Related]
12. Extracellular Vesicles for the Diagnosis of Parkinson's Disease: Systematic Review and Meta-Analysis.
Xylaki M; Chopra A; Weber S; Bartl M; Outeiro TF; Mollenhauer B
Mov Disord; 2023 Sep; 38(9):1585-1597. PubMed ID: 37449706
[TBL] [Abstract][Full Text] [Related]
13. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
[TBL] [Abstract][Full Text] [Related]
14. Novel insights into the role of circular RNAs in Parkinson disease: An emerging renaissance in the management of neurodegenerative diseases.
Dorostgou Z; Yadegar N; Dorostgou Z; Khorvash F; Vakili O
J Neurosci Res; 2022 Sep; 100(9):1775-1790. PubMed ID: 35642104
[TBL] [Abstract][Full Text] [Related]
15. Dopamine-dependent early synaptic and motor dysfunctions induced by α-synuclein in the nigrostriatal circuit.
Tozzi A; Sciaccaluga M; Loffredo V; Megaro A; Ledonne A; Cardinale A; Federici M; Bellingacci L; Paciotti S; Ferrari E; La Rocca A; Martini A; Mercuri NB; Gardoni F; Picconi B; Ghiglieri V; De Leonibus E; Calabresi P
Brain; 2021 Dec; 144(11):3477-3491. PubMed ID: 34297092
[TBL] [Abstract][Full Text] [Related]
16. Regulatory Mechanism of miR-543-3p on GLT-1 in a Mouse Model of Parkinson's Disease.
Wu X; Meng X; Tan F; Jiao Z; Zhang X; Tong H; He X; Luo X; Xu P; Qu S
ACS Chem Neurosci; 2019 Mar; 10(3):1791-1800. PubMed ID: 30676715
[TBL] [Abstract][Full Text] [Related]
17. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
18. Intercellular transfer of pathogenic α-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal.
Zhang S; Eitan E; Wu TY; Mattson MP
Neurobiol Aging; 2018 Jan; 61():52-65. PubMed ID: 29035751
[TBL] [Abstract][Full Text] [Related]
19. The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease.
Lin KJ; Lin KL; Chen SD; Liou CW; Chuang YC; Lin HY; Lin TK
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731450
[TBL] [Abstract][Full Text] [Related]
20. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
